Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
These effects are caused by in utero exposure to maternal IL-5 and resulting fetal eosinophilia.
|
31821769 |
2020 |
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Intravenous reslizumab, a monoclonal IL-5 antibody, is approved for treating severe asthma with eosinophilia.
|
31404668 |
2020 |
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
After epithelial barrier disruption, intranasal OVA application induced higher OVA-specific IgG1 and total IgE in serum, and increased eosinophilia and interleukin-5 in bronchoalveolar lavage (BAL) compared to sham-OVA mice.
|
31769882 |
2019 |
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, treatment of humanized mice with anti-Siglec antibody led to robust depletion of IL-5-induced eosinophilia in vivo.
|
30543818 |
2019 |
Eosinophilic disorder
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This patient also had marked eosinophilia and high levels of thymus and activation-regulated chemokine and interleukin-5 in the serum.
|
29573413 |
2019 |
Eosinophilic disorder
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition to evidence of mast cell activation, mucosa from patients with EoE have increased levels of interleukin 5; supporting eosinophilia; and upregulation of gene expression of eotaxin-3, a chemokine important in eosinophil migration.
|
31690395 |
2019 |
Eosinophilic disorder
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Strong granzyme B<sup>+</sup>, interferon (IFN)-γ<sup>+</sup> CD8<sup>+</sup> cytotoxic T cell and circulating regulatory T (T<sub>reg</sub>) cell responses were noted during allograft rejection, along with significant eosinophilia and elevated serum IL-5 and eotaxin levels.
|
31624262 |
2019 |
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Combined IL-2 Immunocomplex and Anti-IL-5 mAb Treatment Expands Foxp3<sup>+</sup> Treg Cells in the Absence of Eosinophilia and Ameliorates Experimental Colitis.
|
30930900 |
2019 |
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Eosinophilic COPD may represent an overlap with asthma but the mechanism of eosinophilia is uncertain as, although an increase in sputum IL-5 has been detected, anti-IL-5 therapies are not effective in preventing exacerbations.
|
30834543 |
2019 |
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Notably, jejunum eosinophilia in IL-5-deficient-Fabpi-IL-18 mice is significantly induced compared with wild-type mice, which indicates the direct role of induced IL-18 in the tissue accumulation of eosinophils and mast cells.
|
30779114 |
2019 |
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
The role of eosinophilia in atopic diseases, including asthma, is well established, as is the well-known role of IL-5 as a major eosinophilopoeitin and chemoattractant.
|
31415658 |
2019 |
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Similarly, ST2 + IL-5+ HPC numbers were increased in the sputum of COPD patients with airway eosinophilia (p < 0.001).
|
29859068 |
2018 |
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
The most important cytokine involved in the induction, maintenance, and amplification of airway eosinophilia in asthma is interleukin-5 (IL-5), released by both T helper 2 (Th2) lymphocytes and group 2 innate lymphoid cells (ILC2).
|
29862274 |
2018 |
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Upstream Regulator Analysis revealed that not only T-helper 2 (Th2) and the eosinophilia-related molecules (interleukin 4 [IL4], IL5, and colony stimulating factor 2 [CSF2]) reported so far, but also cell cycle regulators (cyclin dependent kinase inhibitor 1A [CDKNA1] and cyclin D1 [CCND1]) and a tissue fibrosis-related molecule (transforming growth factor β [TGFβ]) were identified in ECRSwNP.
|
29337425 |
2018 |
Eosinophilic disorder
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A type 2 immune response was associated with exposure, with increased interleukin-4 (IL-4) production, IL-5 transcription, and eosinophilia.
|
28993458 |
2018 |
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Bone marrow type 2 innate lymphoid cells: a local source of interleukin-5 in interleukin-33-driven eosinophilia.
|
28921511 |
2018 |
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
In both models, targeted deletion of RORα in mouse T<sub>regs</sub> led to exaggerated eosinophilia driven by interleukin-5 (IL-5) production by ILC2s and T<sub>H</sub>2 cells.
|
29500225 |
2018 |
Eosinophilic disorder
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We investigated whether benralizumab, a monoclonal antibody directed against the alpha subunit of the interleukin-5 receptor that significantly reduces the incidence of asthma exacerbations, was also effective as an oral glucocorticoid-sparing therapy in patients relying on oral glucocorticoids to manage severe asthma associated with eosinophilia.
|
28530840 |
2017 |
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
These data are consistent with the hypothesis that the eosinophilia in FE is secondary to dysregulation of IL-5 production in PBMC (and their component subsets).
|
28226398 |
2017 |
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Based on the data presented, I propose omalizumab for patients with an allergic phenotype regardless of their peripheral eosinophilic count, and anti-IL-5 as an alternative in allergic patients with blood eosinophilia in which omalizumab has failed; anti-IL5 for patients with an eosinophilic phenotype and omalizumab as an alternative in patients in whom anti-IL5 fails and IgE ≥30 IU/mL (compassionate use).
|
28948572 |
2017 |
Eosinophilic disorder
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Interestingly, <i>Il17ra<sup>-/-</sup></i> mice without the filaggrin mutation also developed spontaneous progressive skin inflammation with eosinophilia, as well as increased levels of thymic stromal lymphopoietin (TSLP) and IL-5 in the skin.
|
28615416 |
2017 |
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Conspicuous eosinophilia in early-onset FPIES is suggested to be caused by abnormally high IL-5 production.
|
27624222 |
2017 |
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Such a mechanism may explain the protective effect of parasite infection in patients with multiple sclerosis where eosinophilia is induced by IL-5, produced by the immune response to parasites.
|
29163523 |
2017 |
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Interleukin-5 (IL-5) was identified for its role in eosinophil development, maturation, and survival in tissues, which has been related to disease severity and airway eosinophilia.
|
28116937 |
2017 |
Eosinophilic disorder
|
0.100 |
AlteredExpression
|
group |
BEFREE |
IL-5 neutralization before allergen challenge abolished the allergen-induced rise in circulating eosinophils and expression of IL-3 receptors, whereas airway eosinophilia and eosinophil peroxidase deposition were blunted but not eliminated.
|
28862877 |
2017 |